REG - Biofrontera AG - Further re: Subscription Price of New Shares <Origin Href="QuoteRef">B8FGn.DE</Origin>
RNS Number : 6955EBiofrontera AG05 November 2015Ad-hoc Release pursuant to Section15 of the German Securities Trading Act (Wertpapierhandelsgesetz)
Biofrontera AG - subscription price for New Shares from ongoing capital increase determined
Leverkusen, Germany, 05.11.2015 - The board of directors of Biofrontera AG ("Company") has resolved on 27 October, with the approval of the supervisory board, to increase the registered capital of the Company by up to EUR5,893,460 from Authorized Capital I by issuing up to 5,893,460 new no-par registered shares with dividend rights from 1 January 2015 ("New Shares"). Furthermore, the expected date to resolve on the subscription price was set as 5 November 2015.
The subscription price for the New Shares was determined as EUR1.90 on 5 November 2015. This represents a discount of 8.4% over the weighted average trading price of the five preceding trading days, and a discount of 14.7% over the five trading days prior to the announcement of this capital raise.
Further details regarding the subscription offer and the determination of the subscription price may be found in the publication of the subscription offer in the Federal Gazette of 27 October 2015, as well as the securities prospectus dated 27October 2015, which is available on the Company's website (http://www.biofrontera.com/).
The proceeds from the capital increase will be used to cover the operational expenses in the next 12 months and furthermore the establishment of an operational infrastructure for the sales and marketing of Ameluz in the USA.
Enquiries, please contact:
Biofrontera AG
Prof. Hermann Lbbert, Chief Executive Officer
Thomas Schaffer, Chief Financial Officer
+49 (0) 214 87 63 2 0
IR Germany: Brainwell Asset Solutions
Jrgen Benker
+49 (0) 152 08931514
Nomad and Broker: Shore Capital
Bidhi Bhoma / Toby Gibbs
+44(0) 20 7408 4090
IR UK: Seton Services
Toni Vallen
+44(0) 20 7603 6797
Financial PR: Gable Communications
John Bick / Justine James
+44(0) 20 7193 7463
+44 (0)7872 061007
This information is provided by RNSThe company news service from the London Stock ExchangeENDIOEUGGRPGUPAGGA
Recent news on Biofrontera AG
See all newsRCS - Maruho Deutschland - Extraordinary General Meeting on 7 April 2022
AnnouncementREG - AIM Biofrontera AG - Cancellation - Biofrontera AG <Origin Href="QuoteRef">B8FGn.DE</Origin>
AnnouncementREG - Biofrontera AG - Private Placement <Origin Href="QuoteRef">B8FGn.DE</Origin>
AnnouncementREG - Biofrontera AG - Phase III studies update <Origin Href="QuoteRef">B8FGn.DE</Origin>
AnnouncementREG - Biofrontera AG - Excellent results in Ameluz BCC clinical study <Origin Href="QuoteRef">B8FGn.DE</Origin>
Announcement